Professor Kuen-Der Yang's team at Mackay Memorial Hospital has developed a groundbreaking regenerative medicine technology centered around umbilical cord mesenchymal stem cells (ucMSC) and their extracellular vesicles (EVs). This innovation focuses on using the nano-sized EVs secreted by ucMSCs to perform "cell-free transplantation," a new approach in regenerative medicine that replaces the need for the parent stem cells themselves. After years of extensive research, Professor Yang and his team discovered that ucMSCs, when cultured in specific conditions, can be significantly expanded and produce EVs rich in anti-inflammatory and regenerative factors. These EVs can be preserved and transported after cryopreservation or freeze-drying and carry a lower risk of rejection due to the absence of a cell nucleus. This technology, which holds patents in both Taiwan and the United States, is widely applicable in the prevention and treatment of degenerative diseases. It has been licensed to Everfront Biotech Inc. for further production and application. The Mackay research team is also advancing the next-generation design of ucMSC-EVs, creating EVs enriched with multiple anti-inflammatory and regenerative factors, which are expected to contribute to the development of cell-free, non-rejectable, orally-administered, mucosal spray, and skin patch-based regenerative therapies.
Multi-Route Administration and Preclinical Studies: Overcoming Treatment Limitations
A key highlight of the ucMSC and EV technology is its versatile administration routes. These EV formulations can be administered via various methods, including topical, subconjunctival, intranasal, intratracheal, oral, intrathecal, intravenous, intra-arterial, intramuscular, subcutaneous, intra-articular, intracardiac, intraventricular, intraperitoneal, and intratympanic routes. This diversity allows the technology to flexibly address a range of health issues, including inflammatory diseases, dry eye syndrome, degenerative diseases, cancer, and aging. Experimental in vivo studies have demonstrated that ucMSC-EVs exhibit significant therapeutic effects on hearing loss, dry eye syndrome, and Parkinson's disease. Specifically, native EVs and aspirin-preconditioned Aspirin-EVs have shown promising results in preclinical animal studies, effectively improving symptoms of these conditions. These findings not only validate the efficacy of the technology but also lay a solid foundation for future clinical applications. With Mackay's continued efforts to enhance EVs with multiple anti-inflammatory and regenerative factors, ucMSC-EVs are poised to become a critical tool in combating various degenerative diseases.
Pioneering a New Era in Regenerative Medicine
Professor Yang emphasized that ucMSC-derived EVs hold unprecedented potential in the field of regenerative medicine. The team's research demonstrates that ucMSC-EVs perform exceptionally well in combating aging and degenerative diseases. Notably, when these EVs are combined with small molecule activators, their therapeutic effects are further enhanced. Professor Yang noted that this novel technology enables the preparation of native EVs, activator-preconditioned EVs, and activator-encapsulated EVs. These formulations offer the advantages of small doses and convenient administration, while also overcoming the challenges of traditional systemic administration, particularly in targeting the brain. He highlighted that the successful development of this technology will have a profound impact on the treatment of degenerative diseases in an aging society and will promote the shared application of regenerative medicine across three generations.
Resource (mandarin): 再生醫療潛力股！創新臍帶間質幹細胞胞外體有效抗退化
